Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

The increased coronavirus disease 2019 (COVID-19) breakthrough cases pose the need of booster vaccination. We conducted a randomised, double-blinded, controlled, phase 2 trial to assess the immunogenicity and safety of the heterologous prime-boost vaccination with an inactivated COVID-19 vaccine (BB...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaabi, Nawal Al, Yang, Yun Kai, Zhang, Jing, Xu, Ke, Liang, Yu, Kang, Yun, Su, Ji Guo, Yang, Tian, Hussein, Salah, ElDein, Mohamed Saif, Shao, Shuai, Yang, Sen Sen, Lei, Wenwen, Gao, Xue Jun, Jiang, Zhiwei, Wang, Hui, Li, Meng, Mekki, Hanadi Mekki, Zaher, Walid, Mahmoud, Sally, Zhang, Xue, Qu, Chang, Liu, Dan Ying, Yang, Mengjie, Eltantawy, Islam, Xiao, Peng, Wang, Zhao Nian, Yin, Jin Liang, Mao, Xiao Yan, Zhang, Jin, Liu, Ning, Shen, Fu Jie, Qu, Liang, Zhang, Yun Tao, Yang, Xiao Ming, Wu, Guizhen, Li, Qi Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167817/
https://www.ncbi.nlm.nih.gov/pubmed/35665745
http://dx.doi.org/10.1038/s41392-022-00984-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167817/
https://www.ncbi.nlm.nih.gov/pubmed/35665745
http://dx.doi.org/10.1038/s41392-022-00984-2

Ejemplares similares